We've spent a lot of time on this blog discussing what improves HRV and what tanks it. But we haven't addressed the foundational question: why does any of this matter?
The answer: low HRV predicts cardiovascular disease and death. Not loosely—robustly, across multiple large meta-analyses, in both healthy and sick populations.
The Mortality Data
A 2022 meta-analysis pooled data from 32 studies with 38,008 participants. The finding was stark: people in the lowest quartile of RMSSD had a 56% higher risk of death compared to everyone else (HR = 1.56, 95% CI: 1.32-1.85).
This held across ages, sexes, continents, and populations. The researchers tested eight different HRV parameters—all were predictive.
Even more telling: when they ran meta-regression to find effect modifiers, they found none. The HRV-mortality connection didn't weaken with age, sex, or covariate adjustment. It's robust.
The Cardiovascular Event Data
For people who already have cardiovascular disease, the stakes are even higher.
A meta-analysis of 28 cohort studies with 3,094 CVD patients found:
All-cause death: HR = 2.27 (95% CI: 1.72-3.00)
Cardiovascular events: HR = 1.41 (95% CI: 1.16-1.72)
The effects were strongest for people who'd had a heart attack (acute MI). For heart failure patients, the association wasn't significant—possibly because they're already at the floor for autonomic function.
The Primary Prevention Data
What about healthy people who haven't had a heart problem yet?
A meta-analysis of 8 studies with 21,988 participants without known CVD found that low SDNN predicted a first cardiovascular event with RR = 1.35 (comparing lowest to highest levels).
The dose-response relationship was clear: being at the 10th percentile of HRV (vs the 50th percentile) meant a 50% higher risk of a first CV event.
Each 1% increase in SDNN was associated with roughly 1% lower CVD risk.
What Thresholds Matter?
A 2025 synthesis of 67 studies suggested these red flags:
SDNN below 70 ms: MACE hazard ratio of 1.73
LF/HF ratio above 2.5: elevated risk
But don't fixate on population cutoffs. The real value is in your personal trend.
Why Low HRV Is Dangerous
Low HRV reflects:
Reduced vagal tone — Your parasympathetic brake is weak
Sympathetic overdrive — Your stress system is chronically active
Diminished flexibility — Your heart can't adapt to demands
Chronic stress state — Inflammation, metabolic dysregulation
This autonomic imbalance increases arrhythmia risk, promotes inflammation, impairs metabolic regulation, and reduces cardiac reserve. It's not that HRV "causes" heart disease—it's that low HRV reflects the physiological state that causes heart disease.
This Is Why Everything Else Matters
Every intervention we've covered on this blog—resonance breathing, sleep optimization, exercise, blood sugar control, stress management—these all improve HRV.
And if improving HRV reflects shifting your autonomic nervous system toward better balance... then it likely reflects reduced cardiovascular risk.
This is WHY improving your HRV matters beyond the number itself.
The Practical Takeaway
Don't use HRV as a diagnostic tool. That's not what consumer devices are for.
Do use HRV as a tracking metric. If your lifestyle changes improve your personal HRV trend over months, you're likely moving in a cardiovascular-protective direction.
The meta-analyses give us confidence that HRV isn't just a wellness metric—it's a physiological window into real health outcomes. The same habits that improve HRV improve your odds.
Sources
1. Hillebrand S, et al. (2022). Heart rate variability in the prediction of mortality: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews. PMID: 36243195
2. Fang SC, et al. (2020). Heart Rate Variability and Risk of All-Cause Death and Cardiovascular Events. Biological Research for Nursing. PMID: 31558032
3. Hillebrand S, et al. (2013). Heart rate variability and first cardiovascular event in populations without known CVD: meta-analysis. EP Europace. PMID: 23370966
4. Frontiers in Cardiovascular Medicine (2025). Heart rate variability: a multidimensional perspective. DOI: 10.3389/fcvm.2025.1630668